DelveInsight’s ’Spinal Cord Injury–Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Spinal Cord Injury in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Spinal Cord Injury market report provides analysis regarding current treatment practices, emerging drugs like MC001, AST-OPC1, KP-100IT, Elezanumab, Stemirac and other promising candidates like AXER-204, NFX88, market share of the individual therapies, and historical, current and forecasted Spinal Cord Injury market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Spinal Cord Injury treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan



Study Period: 2017–2030

Spinal Cord Injury– Disease Understanding and Treatment Algorithm

Overview

Spinal cord injury occurs when there is any damage to the spinal cord that blocks communication between the brain and the body. After a spinal cord injury, a person’s sensory, motor, and reflex messages are affected and may not pass the spinal cord’s damage. The injury could be complete or incomplete. A complete spinal cord injury causes permanent damage to the area of the spinal cord that is affected. Paraplegia or tetraplegia are results of complete spinal cord injuries, whereas an incomplete spinal cord injury refers to partial damage to the spinal cord.

SCI is characterized by sequential primary, secondary, and chronic phases. The primary injury to the spinal cord is the result of the initial trauma. The primary mechanical insult may occur from compression, shearing, laceration, stretch, distraction, hemorrhage, or vasospasm. Bone or tissue fragments from the primary injury can exacerbate the spinal cord’s swelling, and add to tissue damage. After the central nervous system (CNS) injury, the acute primary and the chronic secondary damage takes place. After the initial mechanical insult, a rapid deformation of CNS tissue happens, causing immediate cell death in the epicenter of the injury site, followed by a cascade of processes leading to the secondary damage. Traumatic injury disrupts spinal white matter tracts resulting in the loss of sensory and motor function. This loss of function is generally permanent due to the limited regenerative capacity of the CNS.

Imaging using MRI or CT scans will provide information about a spinal cord injury, including the type and level of the trauma. Recent guidelines have played an important role in delineating best practices and reducing practice variation in acute clinical treatments. Current management strategies for acute SCI involve early surgical decompression and fixation, vasopressor medications for mean arterial blood pressure (MAP) augmentation to improve spinal cord perfusion, and corticosteroids.


Treatment:

Current management strategies for acute SCI involve early surgical decompression and fixation, vasopressor medications for mean arterial blood pressure (MAP) augmentation to improve spinal cord perfusion, and corticosteroids. According to recent guidelines, current treatment options for chronic spinal cord injury include neurotization or nerve bridging, neurostimulation/neuromodulation, and neuroprosthesis, cell therapy, and neurorehabilitation.

This chapter covers the details of conventional and current medical therapies available for the treatment of Spinal Cord Injury. It also provides Spinal Cord Injury treatment guidelines across the United States and Europe.

DelveInsight’s Spinal Cord Injury market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Spinal Cord Injury treatment pattern and treatment guidelines in the US and Europe.

Epidemiology

The Spinal Cord Injury epidemiology chapters provide insights about historical and current Spinal Cord Injury patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Spinal Cord Injury epidemiology is segmented by the incidence of Spinal Cord Injury and the prevalence of Spinal Cord Injury (sub-segmented into gender, etiology and neurological level). Besides, the report includes a thorough analysis of all segments.

According to DelveInsight’s, the total prevalent population of Spinal Cord Injury in seven major markets was 652,542 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).

Among all the seven major markets, total prevalent cases for Spinal Cord Injury were highest in the United States, followed by Germany and France. Spain accounted for the least number of prevalent cases among the 7MM.

Drug Chapters

This segment encloses the detailed analysis of the drugs in the Spinal Cord Injury pipeline. It also helps understand the Spinal Cord Injury clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

The first-line care of a patient with SCI involves securing the airway, breathing, and circulation, followed by appropriate spinal immobilization in the field to limit further insult of the highly susceptible cord during transport. Emerging therapies like MC001, AST-OPC1, KP-100IT, Elezanumab and Stemirac are expected to bring a positive shift to the overall market.

Market Outlook
The market size of Spinal Cord Injury is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest Spinal Cord Injury market size. Among EU5 countries, Germany, in 2017, had the largest market size with USD 125.04 million, while Spain had the smallest market size of USD 62.42 million.
Drugs Uptake
This section focuses on the rate of uptake of the potential drugs in the Spinal Cord Injury market or expected to get launched in the market during the study period 2017–2030. The analysis covers Spinal Cord Injury market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of SCI market is anticipated to experience a major positive shift in the coming years owing to the expected launch of therapies like MC001, AST-OPC1, KP-100IT, Elezanumab and Stemirac.

Spinal Cord Injury: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Spinal Cord Injury.


KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Spinal Cord Injury domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Spinal Cord Injury Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, Spinal Cord Injury market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Spinal Cord Injury Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Spinal Cord Injury Pipeline Analysis
  • Spinal Cord Injury Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies



Spinal Cord Injury Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Spinal Cord Injury Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake



Spinal Cord Injury Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers



Key Questions

Market Insights:

  • What was the Spinal Cord Injury market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Spinal Cord Injury total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Spinal Cord Injury market size during the forecast period (2017–2030)?
  • At what CAGR, the Spinal Cord Injury market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Spinal Cord Injury market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Spinal Cord Injury market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?



Epidemiology Insights:

  • What are the disease risk, burden and unmet needs of Spinal Cord Injury?
  • What is the historical Spinal Cord Injury patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Spinal Cord Injury in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Spinal Cord Injury?
  • Out of all 7MM countries, which country would have the highest prevalent population of Spinal Cord Injury during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?



Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current options for Spinal Cord Injury treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Spinal Cord Injury in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Spinal Cord Injury?
  • How many therapies are developed by each company for Spinal Cord Injury?
  • How many are emerging therapies in mid-stage, and late stage of development for Spinal Cord Injury treatment?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spinal Cord Injury therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Spinal Cord Injury and their status?
  • What are the key designations that have been granted for the emerging therapies for Spinal Cord Injury?
  • What is the global historical and forecasted market of Spinal Cord Injury?




Reasons To Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Spinal Cord Injury market
  • To understand the future market competition in the Spinal Cord Injury market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Spinal Cord Injury in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Spinal Cord Injury market
  • To understand the future market competition in the Spinal Cord Injury market




Which geography accounted for the largest Spinal Cord Injury market size?

The United States accounted for the largest Spinal Cord Injury market size.

What is forecasted Spinal Cord Injury size in 2030?

DelveInsight estimates an increase in Spinal Cord Injury Market Size during the study period, 2017–2030

What are the present Spinal Cord Injury market drivers?

New approaches for therapy development, Absence of approved therapy, Establishment of specialized care centers, increase in patient population
What are the Spinal Cord Injury market barriers?

Hurdles associated with gathering preclinical data, Proper trial recruitment, Demographic variations in SCI incidence, Ethical concerns associated with stem cell therapies

How many companies are developing drugs for Spinal Cord Injury?

Currently, five key pharma players are developing the drug for Spinal Cord Injury

Which are the leading companies in the Spinal Cord Injury market?

Key Players – StemCyte, Lineage Cell Therapeutics, Kringle Pharma, AbbVie, Nipro Corporation

How is epidemiology segmented for Spinal Cord Injury?

Incident cases of Spinal Cord Injury, Prevalent cases of Spinal Cord Injury (sub-segmented into gender, etiology and neurological level)